{{NoteTA
|G1=ME
}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462090938
| drug_name = 
| INN = 
| type = <!-- empty -->
| image = Levofloxacin skeletal.svg
| width = 250px
| alt = 左氧氟沙星分子的骨架模型
| image2 = Levofloxacin ball-and-stick 3RAE.png
| width2 =
| alt2 = Ball-and-stick model of a levofloxacin molecule
| caption = 

<!-- Clinical data -->
| pronounce = 
| tradename = Levaquin、Tavanic、Leflox、Levobact、Iquix、Cravit等
| Drugs.com = {{drugs.com|monograph|levofloxacin}}
| MedlinePlus = a697040
| licence_EU = yes
| DailyMedID = Levofloxacin
| licence_US = Levofloxacin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_category= 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[口服给药|口服]]，[[静脉注射|注射]] (IV)，[[眼科用药|滴眼液]]
| class = [[喹诺酮类抗生素|喹诺酮类]]
| ATC_prefix = J01
| ATC_suffix = MA12
| ATC_supplemental = {{ATC|S01|AE05}} {{ATC|A02|BD10}} {{ATC|J01|RA05}}
    
<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment = 
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = Rx-only
| legal_US_comment = 
| legal_EU = Rx-only
| legal_EU_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability = 99%
| protein_bound = 31%
| metabolism = <5% 去甲基和[[氧化胺|N-氧化物]]代谢物
| metabolites = 
| onset = 
| elimination_half-life = 6.9小时
| duration_of_action = 
| excretion = [[肾脏|肾脏]]，大部分没有变化（83%）

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 100986-85-4
| CAS_supplemental = 
| PubChem = 149096
| IUPHAR_ligand = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01137
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 131410
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = RIX4E89Y14
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08120
| KEGG2_Ref = 
| KEGG2 = C07660
| ChEBI_Ref = 
| ChEBI = 63598
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 33
| NIAID_ChemDB = 002307
| PDB_ligand = LFX
| synonyms = 

<!-- Chemical and physical data -->
| IUPAC_name = (''S'')-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7''H''-pyrido[''1'',''2'',''3''-''de'']-1,4-benzoxazine-6-carboxylic acid
| C=18 | H=20 | F=1 | N=3 | O=4
| SMILES = C[C@H]1COc2c3n1cc(c(=O)c3cc(c2N4CCN(CC4)C)F)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
| StdInChI_comment = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GSDSWSVVBLHKDQ-JTQLQIEISA-N
| density=1.5±0.1
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}
'''左氧氟沙星'''（[[国际非专有药名|INN]]：Levofloxacin）是一种广谱抗生素。<ref name="ashp">{{Cite web |title=LevoFLOXacin (Systemic) Monograph for Professionals |url=https://www.drugs.com/monograph/levofloxacin-systemic.html |website=Drugs.com |language=en |access-date=2022-06-13 |archive-date=2022-06-15 |archive-url=https://web.archive.org/web/20220615184130/https://www.drugs.com/monograph/levofloxacin-systemic.html }}</ref>它用于治疗多种[[病原细菌|细菌感染]]，包括急性细菌性[[鼻窦炎|鼻窦炎]]、[[肺炎|肺炎]]、[[幽门螺杆菌|幽门螺杆菌]]（与其他药物联合使用）、[[泌尿道感染|尿路感染]]、[[慢性细菌性前列腺炎|慢性细菌性前列腺炎]]和某些类型的[[肠胃炎|肠胃炎]]。<ref name="ashp" />与其他抗生素联用，它可用于治疗[[结核病|肺结核]]、[[脑膜炎|脑膜炎]]或[[盆腔炎|盆腔炎]]。<ref name="ashp" />通常仅在其他选项不可用时才建议使用。<ref>{{Cite web |last=Commissioner |first=Office of the |date=2020-03-24 |title=FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions |url=https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse |website=FDA |language=en |access-date=2022-06-13 |archive-date=2020-12-26 |archive-url=https://web.archive.org/web/20201226192605/https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse }}</ref>它可以通过口服、[[静脉注射|静脉注射]]<ref name="ashp" />和[[滴眼液|滴眼液]]形式使用。<ref name="cm">{{Cite web |title=Levofloxacin ophthalmic Uses, Side Effects & Warnings |url=https://www.drugs.com/mtm/levofloxacin-ophthalmic.html |website=Drugs.com |language=en |access-date=2022-06-13 |archive-date=2017-02-02 |archive-url=https://web.archive.org/web/20170202062127/https://www.drugs.com/mtm/levofloxacin-ophthalmic.html }}</ref>

常见的副作用包括[[恶心|恶心]]、[[腹泻|腹泻]]和睡眠困难。<ref name="ashp" />严重的副作用可能包括[[肌腱断裂|肌腱断裂]]、[[肌腱病變|肌腱炎症]]、[[癫痫发作|癫痫发作]]、[[思覺失調|精神病]]和潜在的永久性[[周边神经病变|周围神经损伤]]。<ref name="ashp" />治疗完成数月后可能出现肌腱损伤。<ref name="ashp" />人们也可能更容易晒伤。<ref name="ashp" />在患有[[重症肌无力|重症肌无力]]的人中，肌肉无力和呼吸问题可能会恶化。<ref name="ashp" />虽然不建议在怀孕期间使用，但风险似乎很低。<ref name="worldcat">{{Cite book|edition=9th ed|title=Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk|url=https://www.worldcat.org/oclc/712672330|publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins|date=2011|location=Philadelphia|isbn=1-60831-708-0|oclc=712672330|first=Roger K.|last=Freeman|first2=Sumner J.|last2=Yaffe|access-date=2022-06-13|archive-date=2020-06-21|archive-url=https://web.archive.org/web/20200621095107/https://www.worldcat.org/title/drugs-in-pregnancy-and-lactation-a-reference-guide-to-fetal-and-neonatal-risk/oclc/712672330}}</ref>在[[母乳哺育|母乳喂养]]期间使用此类中的其他药物似乎是安全的；然而，左氧氟沙星的安全性尚不清楚。<ref name="worldcat" />左氧氟沙星是氟喹诺酮类药物的[[广谱抗生素|广谱抗生素]]。<ref name="worldcat" />它通常会导致细菌死亡。<ref name="ashp" />它是药物[[氧氟沙星|氧氟沙星]]的左旋异构体。<ref name="worldcat" />

左氧氟沙星于1985年获得专利，1996年在美国获准用于医疗用途。<ref name="ashp" /><ref>{{Cite book|title=Analogue-based drug discovery|url=https://www.worldcat.org/oclc/77601762|publisher=Wiley-VCH|date=2006|location=Weinheim|isbn=978-3-527-60749-5|oclc=77601762|first=János|last=Fischer|first2=C. R.|last2=Ganellin|access-date=2022-06-13|archive-date=2020-05-30|archive-url=https://web.archive.org/web/20200530080824/https://www.worldcat.org/title/analogue-based-drug-discovery/oclc/77601762}}</ref>它在[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]中。<ref>{{Cite journal |last=World Health Organization |date=2019 |title=World Health Organization model list of essential medicines: 21st list 2019 |url=https://apps.who.int/iris/handle/10665/325771 |hdl=10665/325771 |language=en |journal= |access-date=2022-06-13 |archive-date=2022-05-16 |archive-url=https://web.archive.org/web/20220516072322/https://apps.who.int/iris/handle/10665/325771 }}</ref>它可作为[[通用名药物|通用名药物]]使用。<ref name="ashp" />2019年，它是美国第182种最常用的处方药，处方量超过300万张。<ref>{{Cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |access-date=2022-06-13 |archive-date=2021-06-26 |archive-url=https://web.archive.org/web/20210626024936/https://clincalc.com/DrugStats/Top300Drugs.aspx }}</ref><ref>{{Cite web|title=Levofloxacin - Drug Usage Statistics|url=https://clincalc.com/DrugStats/Drugs/Levofloxacin|website=ClinCalc DrugStats Database|access-date=2022-06-13|archive-date=2020-07-08|archive-url=https://web.archive.org/web/20200708061502/https://clincalc.com/DrugStats/Drugs/Levofloxacin}}</ref>

== 医疗用途 ==
左氧氟沙星用于治疗感染，包括：[[呼吸道感染|呼吸道感染]]、[[蜂窝组织炎|蜂窝组织炎]]、[[泌尿道感染|尿路感染]]、[[前列腺炎|前列腺炎]]、[[炭疽病|炭疽]]、[[心内膜炎|心内膜炎]]、脑膜炎、盆腔炎、[[旅行者腹泻|旅行者腹泻]]、肺结核和[[鼠疫|鼠疫]]，<ref name="ashp" /><ref name="fda">{{Cite web |date=2016-06 |title=HIGHLIGHTS OF PRESCRIBING INFORMATION |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020634s067,020635s073,021721s034lbl.pdf |website=Drug Databases |format=PDF |language=en-US |access-date=2022-06-13 |archive-date=2021-09-02 |archive-url=https://web.archive.org/web/20210902072814/https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020634s067,020635s073,021721s034lbl.pdf }}</ref>可通过口服、静脉注射<ref name="ashp" />和滴眼剂形式获得。<ref name="cm" />

截至 2016 年，美国食品和药物管理局建议“与氟喹诺酮类抗菌药物相关的严重副作用通常超过有其他治疗选择的急性鼻窦炎、急性支气管炎和单纯性尿路感染患者的益处。对于患有这些疾病的患者 ，氟喹诺酮类药物应该留给那些没有替代治疗选择的人。”<ref name="fda2">{{Cite journal |last=Research |first=Center for Drug Evaluation and |date=2019-02-09 |title=FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain |journal=FDA |language=en |access-date=2022-06-13 |archive-date=2019-04-23 |archive-url=https://web.archive.org/web/20190423133655/https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm }}</ref>

左氧氟沙星用于治疗肺炎、尿路感染和腹部感染。 自 2007 年起，美国传染病学会和[[美国胸科学会|美国胸科学会]]推荐左氧氟沙星和其他呼吸道氟喹啉作为社区获得性肺炎的一线治疗，当存在心脏、肺或肝病等合并症或住院治疗时 必需的。<ref>{{Cite journal |last=Mandell |first=Lionel A. |last2=Wunderink |first2=Richard G. |last3=Anzueto |first3=Antonio |last4=Bartlett |first4=John G. |last5=Campbell |first5=G. Douglas |last6=Dean |first6=Nathan C. |last7=Dowell |first7=Scott F. |last8=File |first8=Thomas M. |last9=Musher |first9=Daniel M. |last10=Niederman |first10=Michael S. |last11=Torres |first11=Antonio |date=2007-03-01 |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |url=https://pubmed.ncbi.nlm.nih.gov/17278083 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=44 Suppl 2 |doi=10.1086/511159 |issn=1537-6591 |pmc=7107997 |pmid=17278083 |access-date=2022-06-13 |archive-date=2022-06-06 |archive-url=https://web.archive.org/web/20220606202324/https://pubmed.ncbi.nlm.nih.gov/17278083/ }}</ref>左氧氟沙星在呼吸机相关和医疗保健相关肺炎的推荐治疗方案中也发挥着重要作用。<ref>{{Cite journal |last=File |first=Thomas M. |date=2010-08-01 |title=Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines |url=https://pubmed.ncbi.nlm.nih.gov/20597671 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=51 Suppl 1 |doi=10.1086/653048 |issn=1537-6591 |pmid=20597671 |access-date=2022-06-13 |archive-date=2022-05-29 |archive-url=https://web.archive.org/web/20220529175429/https://pubmed.ncbi.nlm.nih.gov/20597671/ }}</ref>

自 2010 年起，它被 IDSA 推荐为成人导管相关尿路感染的一线治疗选择。<ref>{{Cite journal |last=Hooton |first=Thomas M. |last2=Bradley |first2=Suzanne F. |last3=Cardenas |first3=Diana D. |last4=Colgan |first4=Richard |last5=Geerlings |first5=Suzanne E. |last6=Rice |first6=James C. |last7=Saint |first7=Sanjay |last8=Schaeffer |first8=Anthony J. |last9=Tambayh |first9=Paul A. |last10=Tenke |first10=Peter |last11=Nicolle |first11=Lindsay E. |date=2010-03-01 |title=Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America |url=https://pubmed.ncbi.nlm.nih.gov/20175247 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=50 |issue=5 |doi=10.1086/650482 |issn=1537-6591 |pmid=20175247 |access-date=2022-06-13 |archive-date=2022-06-06 |archive-url=https://web.archive.org/web/20220606201955/https://pubmed.ncbi.nlm.nih.gov/20175247/ }}</ref>与[[甲硝唑|甲硝唑]]联用被推荐作为社区获得性轻度至中度严重腹腔感染成年患者的几种一线治疗选择之一。<ref>{{Cite journal |last=Solomkin |first=Joseph S. |last2=Mazuski |first2=John E. |last3=Bradley |first3=John S. |last4=Rodvold |first4=Keith A. |last5=Goldstein |first5=Ellie J. C. |last6=Baron |first6=Ellen J. |last7=O'Neill |first7=Patrick J. |last8=Chow |first8=Anthony W. |last9=Dellinger |first9=E. Patchen |last10=Eachempati |first10=Soumitra R. |last11=Gorbach |first11=Sherwood |date=2010-01-15 |title=Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America |url=https://pubmed.ncbi.nlm.nih.gov/20034345 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=50 |issue=2 |doi=10.1086/649554 |issn=1537-6591 |pmid=20034345 |access-date=2022-06-13 |archive-date=2022-06-20 |archive-url=https://web.archive.org/web/20220620205107/https://pubmed.ncbi.nlm.nih.gov/20034345/ }}</ref>IDSA 还建议将其与利福平联合用作人工关节感染的一线治疗。<ref>{{Cite journal |last=Osmon |first=Douglas R. |last2=Berbari |first2=Elie F. |last3=Berendt |first3=Anthony R. |last4=Lew |first4=Daniel |last5=Zimmerli |first5=Werner |last6=Steckelberg |first6=James M. |last7=Rao |first7=Nalini |last8=Hanssen |first8=Arlen |last9=Wilson |first9=Walter R. |last10=Infectious Diseases Society of America |date=2013-01 |title=Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America |url=https://pubmed.ncbi.nlm.nih.gov/23230301 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=56 |issue=1 |doi=10.1093/cid/cis966 |issn=1537-6591 |pmid=23230301 |access-date=2022-06-13 |archive-date=2022-06-18 |archive-url=https://web.archive.org/web/20220618052705/https://pubmed.ncbi.nlm.nih.gov/23230301/ }}</ref>美国泌尿学协会推荐左氧氟沙星作为前列腺活检时预防细菌性前列腺炎的一线治疗。<ref>{{Cite web |title=The Prevention and Treatment of the More Common Complications Related to Prostate Biopsy Update |url=https://www.auanet.org/guidelines/guidelines/prostate-needle-biopsy-complications |website=American Urological Association |access-date=2022-06-13 |archive-date=2022-03-07 |archive-url=https://web.archive.org/web/20220307191512/https://www.auanet.org/guidelines/guidelines/prostate-needle-biopsy-complications }}</ref>自 2004 年起，研究该病症的 NIH 研究网络建议治疗细菌性前列腺炎。<ref>{{Cite journal |last=Schaeffer |first=Anthony J. |last2=National Institute of Diabetes and Digestive and Kidney Diseases of the US National Institutes of Health |date=2004-09 |title=NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for bacterial prostatitis |url=https://pubmed.ncbi.nlm.nih.gov/15364307 |journal=International Journal of Antimicrobial Agents |volume=24 Suppl 1 |doi=10.1016/j.ijantimicag.2004.02.009 |issn=0924-8579 |pmid=15364307 |access-date=2022-06-13 |archive-date=2022-05-29 |archive-url=https://web.archive.org/web/20220529175500/https://pubmed.ncbi.nlm.nih.gov/15364307/ }}</ref>

左氧氟沙星和其他氟喹诺酮类药物也被广泛用于治疗简单的社区获得性呼吸道和泌尿道感染，主要医学学会普遍建议使用较旧的窄谱药物以避免氟喹诺酮类药物耐药性的发展。由于其广泛使用，大肠杆菌和肺炎克雷伯菌等常见病原体已产生耐药性。截至 2013 年，在许多国家，与这些病原体相关的医疗相关感染的耐药率超过 20%。<ref>{{Cite web |date=2015-11-16 |title=Antimicrobial resistance surveillance in Europe 2014 |url=https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2014 |website=European Centre for Disease Prevention and Control |language=en |access-date=2022-06-13 |archive-date=2016-04-14 |archive-url=https://web.archive.org/web/20160414110905/http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf }}</ref><ref>{{Cite web |title=Antibiotic resistance threats in the United States, 2013 |url=https://stacks.cdc.gov/view/cdc/20705 |website=Centers for Disease Control and Prevention |access-date=2022-06-13 |archive-date=2022-04-01 |archive-url=https://web.archive.org/web/20220401081442/https://stacks.cdc.gov/view/cdc/20705 }}</ref>

左氧氟沙星也用作抗生素眼药水，以防止细菌感染。 与单独使用滴眼剂或注射剂相比，在[[白内障手术|白内障手术]]期间使用左氧氟沙星滴眼液以及抗生素注射[[头孢呋辛|头孢呋辛]]或[[青霉素|青霉素]]可降低发生[[眼内炎|眼内炎]]的几率。<ref>{{Cite journal |last=Gower |first=Emily W. |last2=Lindsley |first2=Kristina |last3=Tulenko |first3=Samantha E. |last4=Nanji |first4=Afshan A. |last5=Leyngold |first5=Ilya |last6=McDonnell |first6=Peter J. |date=2017-02-13 |title=Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery |url=https://pubmed.ncbi.nlm.nih.gov/28192644 |journal=The Cochrane Database of Systematic Reviews |volume=2 |doi=10.1002/14651858.CD006364.pub3 |issn=1469-493X |pmc=5375161 |pmid=28192644 |access-date=2022-06-13 |archive-date=2022-06-15 |archive-url=https://web.archive.org/web/20220615164919/https://pubmed.ncbi.nlm.nih.gov/28192644/ }}</ref>

=== 怀孕和哺乳 ===
根据 FDA 批准的处方信息，左氧氟沙星是妊娠C类。<ref name="fda" />该名称表明动物生殖研究显示对胎儿有不利影响，并且没有对人类进行充分和良好对照的研究，但在某些情况下，对母亲的潜在益处可能超过对胎儿的风险。 现有数据表明未出生婴儿的风险较低。<ref name="worldcat" />在孕早期接触喹诺酮类药物（包括左氧氟沙星）与死产、早产、出生缺陷或低出生体重的风险增加无关。<ref>{{Cite journal |last=Ziv |first=Aviva |last2=Masarwa |first2=Reem |last3=Perlman |first3=Amichai |last4=Ziv |first4=Danny |last5=Matok |first5=Ilan |date=2018-03-26 |title=Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis |url=https://pubmed.ncbi.nlm.nih.gov/29582196 |journal=Pharmaceutical Research |volume=35 |issue=5 |doi=10.1007/s11095-018-2383-8 |issn=1573-904X |pmid=29582196 |access-date=2022-06-13 |archive-date=2022-05-29 |archive-url=https://web.archive.org/web/20220529175453/https://pubmed.ncbi.nlm.nih.gov/29582196/ }}</ref>左氧氟沙星确实会渗透到母乳中，通过母乳喂养婴儿的左氧氟沙星浓度预计会很低。<ref name="nih">{{Cite book|chapter=Levofloxacin|title=Drugs and Lactation Database (LactMed)|url=http://www.ncbi.nlm.nih.gov/books/NBK501002/|publisher=National Library of Medicine (US)|date=2006|location=Bethesda (MD)|pmid=30000061|access-date=2022-06-13|archive-date=2021-03-05|archive-url=https://web.archive.org/web/20210305163943/https://www.ncbi.nlm.nih.gov/books/NBK501002/}}</ref>由于对婴儿有潜在风险，制造商不建议哺乳母亲服用左氧氟沙星。<ref name="fda" />然而，风险似乎非常低，左氧氟沙星可用于母乳喂养的母亲，并适当监测婴儿，并在服用左氧氟沙星后延迟母乳喂养 4-6 小时。<ref name="nih" />

=== 儿童 ===
左氧氟沙星在大多数国家都没有被批准用于治疗儿童，除非是独特和危及生命的感染，因为它与该人群的肌肉骨骼损伤风险升高有关，这是它与其他氟喹诺酮类药物共有的特性。

在美国，左氧氟沙星被批准用于治疗 6 个月以上儿童的炭疽和鼠疫。<ref name="fda" />

左氧氟沙星被儿科传染病学会和美国传染病学会推荐作为耐青霉素肺炎链球菌引起的小儿肺炎的一线治疗药物，以及青霉素敏感病例治疗的二线药物。<ref>{{Cite journal |last=Bradley |first=John S. |last2=Byington |first2=Carrie L. |last3=Shah |first3=Samir S. |last4=Alverson |first4=Brian |last5=Carter |first5=Edward R. |last6=Harrison |first6=Christopher |last7=Kaplan |first7=Sheldon L. |last8=Mace |first8=Sharon E. |last9=McCracken |first9=George H. |last10=Moore |first10=Matthew R. |last11=St Peter |first11=Shawn D. |date=2011-10 |title=The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America |url=https://pubmed.ncbi.nlm.nih.gov/21880587 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=53 |issue=7 |doi=10.1093/cid/cir531 |issn=1537-6591 |pmc=7107838 |pmid=21880587 |access-date=2022-06-13 |archive-date=2022-06-14 |archive-url=https://web.archive.org/web/20220614233218/https://pubmed.ncbi.nlm.nih.gov/21880587/ }}</ref>

在一项研究中，<ref name="fda" /><ref>{{Cite journal |last=Noel |first=Gary J. |last2=Bradley |first2=John S. |last3=Kauffman |first3=Ralph E. |last4=Duffy |first4=Ciaran M. |last5=Gerbino |first5=Peter G. |last6=Arguedas |first6=Adriano |last7=Bagchi |first7=Partha |last8=Balis |first8=Dainius A. |last9=Blumer |first9=Jeffrey L. |date=2007-10 |title=Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders |url=https://pubmed.ncbi.nlm.nih.gov/17901792 |journal=The Pediatric Infectious Disease Journal |volume=26 |issue=10 |doi=10.1097/INF.0b013e3180cbd382 |issn=0891-3668 |pmid=17901792 |access-date=2022-06-13 |archive-date=2022-05-29 |archive-url=https://web.archive.org/web/20220529175416/https://pubmed.ncbi.nlm.nih.gov/17901792/ }}</ref>作为三项疗效试验的一部分，对 1534 名接受左氧氟沙星治疗的青少年患者（6个月至16岁）进行了随访，以评估治疗后 12 个月内发生的所有肌肉骨骼事件。 在 12 个月的随访中，肌肉骨骼不良事件的累积发生率为 3.4%，而在接受其他抗生素治疗的 893 名患者中为 1.8%。 在左氧氟沙星治疗组中，大约三分之二的这些肌肉骨骼不良事件发生在前 60 天，86% 为轻度，17% 为中度，并且均在无长期后遗症的情况下得到缓解。

=== 抗菌谱 ===
左氧氟沙星和后来的氟喹诺酮类药物统称为“呼吸道喹诺酮类药物”，以区别于早期的氟喹诺酮类药物，后者对重要的呼吸道病原体肺炎链球菌表现出适度的活性。<ref>{{Cite journal |last=Wispelwey |first=Brian |last2=Schafer |first2=Katherine R. |date=2010-11 |title=Fluoroquinolones in the management of community-acquired pneumonia in primary care |url=https://pubmed.ncbi.nlm.nih.gov/21073291 |journal=Expert Review of Anti-Infective Therapy |volume=8 |issue=11 |doi=10.1586/eri.10.110 |issn=1744-8336 |pmid=21073291 |access-date=2022-06-13 |archive-date=2022-06-18 |archive-url=https://web.archive.org/web/20220618044321/https://pubmed.ncbi.nlm.nih.gov/21073291/ }}</ref>

与早期的氟喹诺酮衍生物如环丙沙星相比，该药物对重要的呼吸道病原体肺炎链球菌表现出更强的活性。 出于这个原因，它与最近开发的氟喹诺酮类药物如莫西沙星和吉米沙星一起被认为是一种“呼吸用氟喹诺酮类药物”。 它对革兰氏阴性菌，特别是铜绿假单胞菌的活性低于[[环丙沙星|环丙沙星]]，并且缺乏[[莫西沙星|莫西沙星]]和[[吉米沙星|吉米沙星]]的[[耐甲氧西林金黄色葡萄球菌|耐甲氧西林金黄色葡萄球菌]]活性。<ref name="karger">{{Cite journal |last=Lafredo |first=S. C. |last2=Foleno |first2=B. D. |last3=Fu |first3=K. P. |date=1993 |title=Induction of resistance of Streptococcus pneumoniae to quinolones in vitro |url=https://www.karger.com/Article/Abstract/238971 |journal=Chemotherapy |volume=39 |issue=1 |doi=10.1159/000238971 |issn=0009-3157 |pmid=8383031 |access-date=2022-06-13 |archive-date=2022-06-22 |archive-url=https://web.archive.org/web/20220622074233/https://pubmed.ncbi.nlm.nih.gov/8383031/ }}</ref><ref>{{Cite journal |last=Schlesinger |first=Hilde S. |date=1969-03 |title=Beyond the Range of Sound—The Non-Otological Aspects of Deafness |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1503449/ |journal=California Medicine |volume=110 |issue=3 |issn=0008-1264 |pmc=1503449 |pmid=5773480 |access-date=2022-06-13 |archive-date=2022-06-19 |archive-url=https://web.archive.org/web/20220619084149/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1503449/ }}</ref><ref>{{Cite journal |last=Blondeau |first=J. M. |date=1999-05 |title=A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones' |url=https://pubmed.ncbi.nlm.nih.gov/10382869 |journal=The Journal of Antimicrobial Chemotherapy |volume=43 Suppl B |doi=10.1093/jac/43.suppl_2.1 |issn=0305-7453 |pmid=10382869 |access-date=2022-06-13 |archive-date=2022-06-15 |archive-url=https://web.archive.org/web/20220615152626/https://pubmed.ncbi.nlm.nih.gov/10382869/ }}</ref><ref>{{Cite journal |last=Akuamoa-Boateng |first=Dennis |last2=Linde |first2=Philipp |last3=Steiner |first3=Gloria |last4=Jablonska |first4=Karolina |last5=Baues |first5=Christian |last6=Marnitz |first6=Simone |date=2022 |title=COVID-19 und die Onkologie: agiles Patientenmanagement |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980783/ |journal=Forum |volume=37 |issue=3 |doi=10.1007/s12312-022-01069-5 |issn=0947-0255 |pmc=8980783 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616100039/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980783/ }}</ref>左氧氟沙星对[[厭氧生物|厌氧菌]]表现出中等活性，对[[結核桿菌|结核分枝杆菌]]和其他分枝杆菌（包括鸟分枝杆菌复合物）的效力大约是氧氟沙星的两倍。<ref>{{Cite journal |last=Bosso |first=John |date=1998-04-08 |title=New and Emerging Quinolone Antibiotics: |url=http://haworthpress.com/store/ArticleAbstract.asp?ID=80656 |journal=Journal of Infectious Disease Pharmacotherapy |volume=2 |issue=4 |doi=10.1300/J100v02n04_06 |issn=1068-7777}}</ref>

其活性谱包括导致呼吸道、泌尿道、胃肠道和腹部感染的大多数细菌病原体菌株，包括[[革兰氏阴性菌|革兰氏阴性菌]]（[[大肠杆菌|大肠杆菌]]、[[流感嗜血杆菌|流感嗜血杆菌]]、[[克雷伯氏肺炎菌|克雷伯氏肺炎菌]]、[[嗜肺军团菌|嗜肺军团菌]]、卡他莫拉菌、奇异变形杆菌和[[綠膿桿菌|铜绿假单胞菌]]）， [[革兰氏阳性菌|革兰氏阳性菌]]（对甲氧西林敏感但不耐[[甲氧西林|甲氧西林]]的[[金黄色葡萄球菌|金黄色葡萄球菌]]、[[肺炎链球菌|肺炎链球菌]]、表皮葡萄球菌、粪肠球菌和化脓性链球菌）和非典型细菌病原体（肺炎衣原体和[[肺炎支原体|肺炎支原体]]）。 与早期的氟喹啉类抗生素如环丙沙星相比，左氧氟沙星对革兰氏阳性菌表现出更大的活性<ref name="karger" />但对革兰氏阴性菌的活性较低，<ref>{{Cite journal |last=Yamane |first=N. |last2=Jones |first2=R. N. |last3=Frei |first3=R. |last4=Hoban |first4=D. J. |last5=Pignatari |first5=A. C. |last6=Marco |first6=F. |date=1994-04 |title=Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin |url=https://pubmed.ncbi.nlm.nih.gov/8077990 |journal=Journal of Chemotherapy (Florence, Italy) |volume=6 |issue=2 |doi=10.1080/1120009x.1994.11741134 |issn=1120-009X |pmid=8077990 |access-date=2022-06-13 |archive-date=2022-05-29 |archive-url=https://web.archive.org/web/20220529175438/https://pubmed.ncbi.nlm.nih.gov/8077990/ }}</ref>尤其是铜绿假单胞菌。

=== 耐药性 ===
对氟喹诺酮类药物的耐药性在葡萄球菌和假单胞菌中很常见。 抵抗以多种方式发生。 一种机制是通过改变拓扑异构酶IV酶。 带有 Ser-81-->Phe 和 Ser-79-->Phe 突变的肺炎链球菌 Gyr A + Par C 双突变形式对环丙沙星的反应性降低了 8 到 16 倍。<ref>{{Cite journal |last=Hawkey |first=Peter M. |date=2003-05 |title=Mechanisms of quinolone action and microbial response |url=https://pubmed.ncbi.nlm.nih.gov/12702701 |journal=The Journal of Antimicrobial Chemotherapy |volume=51 Suppl 1 |doi=10.1093/jac/dkg207 |issn=0305-7453 |pmid=12702701 |access-date=2022-06-13 |archive-date=2022-06-22 |archive-url=https://web.archive.org/web/20220622064414/https://pubmed.ncbi.nlm.nih.gov/12702701/ }}</ref>

== 禁忌症和相互作用 ==
包装插页提到，已知对左氧氟沙星或其他喹诺酮类药物过敏的患者应避免使用左氧氟沙星。<ref name="fda" /><ref name="emc">{{Cite web |title=Levofloxacin 250mg and 500mg Tablets - Patient Information Leaflet (PIL) |url=https://www.medicines.org.uk/emc/medicine/24625 |website=electronic medicines compendium |access-date=2022-06-13 |archive-date=2016-08-26 |archive-url=https://web.archive.org/web/20160826141227/https://www.medicines.org.uk/emc/medicine/24625 }}</ref>

与所有氟喹诺酮类药物一样，左氧氟沙星禁用于[[癫痫|癫痫]]或其他癫痫病患者，以及有喹诺酮类药物相关肌腱断裂病史的患者。<ref name="fda" /><ref name="emc" />

左氧氟沙星可能会延长部分人群的QT间期，尤其是老年人，左氧氟沙星不宜用于有[[长QT综合征|长QT综合征]]家族史或QT长、慢性[[低鉀血症|低钾]]的人群，不宜与其他具有 延长QT间期。<ref name="fda" />

与环丙沙星不同，左氧氟沙星似乎不会使药物代谢酶 [[CYP1A2|CYP1A2]] 失活。 因此，使用这种酶的药物，如[[茶碱|茶碱]]，不会与左氧氟沙星相互作用。它是[[CYP2C9|CYP2C9]]的弱抑制剂，<ref>{{Cite journal |last=Zhang |first=Li |last2=Wei |first2=Min-ji |last3=Zhao |first3=Cai-yun |last4=Qi |first4=Hui-min |date=2008-12 |title=Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes |url=https://pubmed.ncbi.nlm.nih.gov/19026171 |journal=Acta Pharmacologica Sinica |volume=29 |issue=12 |doi=10.1111/j.1745-7254.2008.00908.x |issn=1745-7254 |pmid=19026171 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616204433/https://pubmed.ncbi.nlm.nih.gov/19026171/ }}</ref>具有阻止[[华法林|华法林]]和苯丙香豆素分解的潜力。这可能会导致华法林等药物的更多作用，从而导致更多潜在的副作用，例如出血。<ref>{{Cite journal |last=Schelleman |first=H. |last2=Bilker |first2=W. B. |last3=Brensinger |first3=C. M. |last4=Han |first4=X. |last5=Kimmel |first5=S. E. |last6=Hennessy |first6=S. |date=2008-11 |title=Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding |url=https://pubmed.ncbi.nlm.nih.gov/18685566 |journal=Clinical Pharmacology and Therapeutics |volume=84 |issue=5 |doi=10.1038/clpt.2008.150 |issn=1532-6535 |pmc=2574587 |pmid=18685566 |access-date=2022-06-13 |archive-date=2022-06-18 |archive-url=https://web.archive.org/web/20220618024608/https://pubmed.ncbi.nlm.nih.gov/18685566/ }}</ref>

[[非甾体类抗炎药|非甾体类抗炎药]]与大剂量氟喹诺酮类药物联合使用可能导致癫痫发作。<ref>{{Cite journal |last=Domagala |first=J. M. |date=1994-04 |title=Structure-activity and structure-side-effect relationships for the quinolone antibacterials |url=https://pubmed.ncbi.nlm.nih.gov/8056688 |journal=The Journal of Antimicrobial Chemotherapy |volume=33 |issue=4 |doi=10.1093/jac/33.4.685 |issn=0305-7453 |pmid=8056688 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616222329/https://pubmed.ncbi.nlm.nih.gov/8056688/ }}</ref>

当左氧氟沙星与含有氢氧化镁或氢氧化铝的抗酸剂一起服用时，两者结合形成难以从肠道吸收的不溶性盐。左氧氟沙星的血清峰值浓度可能降低90%或更多，这可能会阻止左氧氟沙星发挥作用。当左氧氟沙星与铁补充剂和含锌的多种维生素一起服用时，也报告了类似的结果。<ref>{{Cite journal |last=Rodvold |first=K. A. |last2=Piscitelli |first2=S. C. |date=1993-08 |title=New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety |url=https://pubmed.ncbi.nlm.nih.gov/8399914 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=17 Suppl 1 |doi=10.1093/clinids/17.supplement_1.s192 |issn=1058-4838 |pmid=8399914 |access-date=2022-06-13 |archive-date=2022-06-18 |archive-url=https://web.archive.org/web/20220618202707/https://pubmed.ncbi.nlm.nih.gov/8399914/ }}</ref><ref>{{Cite journal |last=Tanaka |first=M. |last2=Kurata |first2=T. |last3=Fujisawa |first3=C. |last4=Ohshima |first4=Y. |last5=Aoki |first5=H. |last6=Okazaki |first6=O. |last7=Hakusui |first7=H. |date=1993-10 |title=Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide |url=https://pubmed.ncbi.nlm.nih.gov/8257141 |journal=Antimicrobial Agents and Chemotherapy |volume=37 |issue=10 |doi=10.1128/AAC.37.10.2173 |issn=0066-4804 |pmc=192246 |pmid=8257141 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616204631/https://pubmed.ncbi.nlm.nih.gov/8257141/ }}</ref>

2011年一项审查氟喹诺酮类药物肌肉骨骼并发症的审查提出了运动员用药指南，呼吁尽可能避免使用所有氟喹诺酮类抗生素，如果使用它们：确保获得肌肉骨骼风险的知情同意，并告知教练组；如果使用氟喹诺酮类药物，请勿使用任何皮质类固醇；在治疗期间考虑[[營養補充品|膳食补充剂]]镁和抗氧化剂；减少训练直到抗生素疗程结束，然后小心增加恢复正常；并在课程结束后监测六个月，如果出现症状，则停止所有体育活动。<ref name="wiley">{{Cite journal |last=Hall |first=Mederic M. |last2=Finnoff |first2=Jonathan T. |last3=Smith |first3=Jay |date=2011-02 |title=Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population |url=https://onlinelibrary.wiley.com/doi/abs/10.1016/j.pmrj.2010.10.003 |journal=PM & R: the journal of injury, function, and rehabilitation |volume=3 |issue=2 |doi=10.1016/j.pmrj.2010.10.003 |issn=1934-1482 |pmid=21333952 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613072031/https://pubmed.ncbi.nlm.nih.gov/21333952/ }}</ref>

== 不良反应 ==
不良反应通常为轻度至中度。 然而，有时会出现严重、致残和可能不可逆的不良反应，因此建议限制氟喹诺酮类药物的使用。

其中最突出的是不良反应，该不良反应在 2016 年成为FDA[[黑框警告|黑框警告]]的原因。<ref name="fda2" />FDA 写道：“FDA的一项安全审查表明，全身使用氟喹诺酮类药物（即片剂、胶囊剂和注射剂）会导致致残和可能同时发生的永久性严重不良反应。这些不良反应可能涉及肌腱、肌肉、关节、神经和中枢神经系统。”<ref name="fda2" />在极少数情况下，氟喹诺酮类抗生素（包括左氧氟沙星）可能会发生肌腱炎或肌腱断裂。<ref>{{Cite journal |last=Stephenson |first=Anne L. |last2=Wu |first2=Wei |last3=Cortes |first3=Daniel |last4=Rochon |first4=Paula A. |date=2013-09 |title=Tendon Injury and Fluoroquinolone Use: A Systematic Review |url=https://pubmed.ncbi.nlm.nih.gov/23888427 |journal=Drug Safety |volume=36 |issue=9 |doi=10.1007/s40264-013-0089-8 |issn=1179-1942 |pmid=23888427 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613074155/https://pubmed.ncbi.nlm.nih.gov/23888427/ }}</ref>此类损伤，包括肌腱断裂，在停止治疗后长达 6 个月内观察到； 较高剂量的氟喹诺酮类药物、老年人、移植患者以及当前或历史使用过[[皮质类固醇|皮质类固醇]]的患者风险较高。<ref>{{Cite journal |last=Khaliq |first=Yasmin |last2=Zhanel |first2=George G. |date=2003-06-01 |title=Fluoroquinolone-associated tendinopathy: a critical review of the literature |url=https://pubmed.ncbi.nlm.nih.gov/12766835 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=36 |issue=11 |doi=10.1086/375078 |issn=1537-6591 |pmid=12766835 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613074155/https://pubmed.ncbi.nlm.nih.gov/12766835/ }}</ref><ref>{{Cite journal |last=Kim |first=Grace K. |date=2010-4 |title=The Risk of Fluoroquinolone-induced Tendinopathy and Tendon Rupture |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921747/ |journal=The Journal of clinical and aesthetic dermatology |volume=3 |issue=4 |issn=1941-2789 |pmc=2921747 |pmid=20725547 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616064746/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921747/ }}</ref>左氧氟沙星的美国标签还包含一个黑框警告，警告神经系统疾病重症肌无力症状的恶化。<ref name="fda" /><ref>{{Cite journal |last=Jones |first=S. Christopher |last2=Sorbello |first2=Alfred |last3=Boucher |first3=Robert M. |date=2011-10-01 |title=Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review |url=https://pubmed.ncbi.nlm.nih.gov/21879778 |journal=Drug Safety |volume=34 |issue=10 |doi=10.2165/11593110-000000000-00000 |issn=1179-1942 |pmid=21879778 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616222841/https://pubmed.ncbi.nlm.nih.gov/21879778/ }}</ref>同样，英国药品和保健品监管机构的建议警告罕见但致残且可能不可逆的不良反应，并建议限制使用这些药物。<ref>{{Cite web |title=Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects |url=https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects |website=GOV.UK |language=en |access-date=2022-06-13 |archive-date=2020-07-18 |archive-url=https://web.archive.org/web/20200718052754/https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects }}</ref>增加年龄和使用皮质类固醇似乎会增加肌肉骨骼并发症的风险。<ref name="wiley" />

许多其他不常见但严重的不良事件与氟喹诺酮类药物的使用有关，有不同程度的证据支持因果关系。这些包括过敏反应、肝毒性、中枢神经系统影响（包括癫痫发作和精神影响）、QT 间期延长、血糖紊乱和[[感光性|光敏性]]等。<ref name="fda" /><ref name="emc" />与其他氟喹诺酮类药物相比，左氧氟沙星可能产生更少的这些罕见的严重不良反应。<ref>{{Cite journal |last=Carbon |first=C. |date=2001 |title=Comparison of side effects of levofloxacin versus other fluoroquinolones |url=https://pubmed.ncbi.nlm.nih.gov/11549784 |journal=Chemotherapy |volume=47 Suppl 3 |doi=10.1159/000057839 |issn=0009-3157 |pmid=11549784 |access-date=2022-06-13 |archive-date=2022-06-22 |archive-url=https://web.archive.org/web/20220622122520/https://pubmed.ncbi.nlm.nih.gov/11549784/ }}</ref>关于左氧氟沙星和其他氟喹诺酮类药物是否以及在何种程度上比其他广谱抗菌药物更频繁地产生严重不良反应，医学文献存在一些分歧。<ref>{{Cite journal |last=Liu |first=Hans H. |date=2010-05-01 |title=Safety profile of the fluoroquinolones: focus on levofloxacin |url=https://pubmed.ncbi.nlm.nih.gov/20397737 |journal=Drug Safety |volume=33 |issue=5 |doi=10.2165/11536360-000000000-00000 |issn=1179-1942 |pmid=20397737 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613074202/https://pubmed.ncbi.nlm.nih.gov/20397737/ }}</ref><ref>{{Cite journal |last=Karageorgopoulos |first=Drosos E. |last2=Giannopoulou |first2=Konstantina P. |last3=Grammatikos |first3=Alexandros P. |last4=Dimopoulos |first4=George |last5=Falagas |first5=Matthew E. |date=2008-03-25 |title=Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials |url=https://pubmed.ncbi.nlm.nih.gov/18362380 |journal=CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne |volume=178 |issue=7 |doi=10.1503/cmaj.071157 |issn=1488-2329 |pmc=2267830 |pmid=18362380 |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616181158/https://pubmed.ncbi.nlm.nih.gov/18362380/ }}</ref><ref>{{Cite journal |last=Lipsky |first=B. A. |last2=Baker |first2=C. A. |date=1999-02 |title=Fluoroquinolone toxicity profiles: a review focusing on newer agents |url=https://pubmed.ncbi.nlm.nih.gov/10064255 |journal=Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |volume=28 |issue=2 |doi=10.1086/515104 |issn=1058-4838 |pmid=10064255 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613074333/https://pubmed.ncbi.nlm.nih.gov/10064255/ }}</ref><ref>{{Cite journal |last=Stahlmann |first=Ralf |last2=Lode |first2=Hartmut M. |date=2013-07 |title=Risks associated with the therapeutic use of fluoroquinolones |url=https://pubmed.ncbi.nlm.nih.gov/23651367 |journal=Expert Opinion on Drug Safety |volume=12 |issue=4 |doi=10.1517/14740338.2013.796362 |issn=1744-764X |pmid=23651367 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613074202/https://pubmed.ncbi.nlm.nih.gov/23651367/ }}</ref>

有一些左氧氟沙星与特发性颅内高压相关的病例报告。<ref>{{Cite journal |last=Rissardo |first=JamirPitton |last2=Fornari Caprara |first2=AnaLetícia |date=2019 |title=Intracranial hypertension secondary to levofloxacin-therapy |url=http://www.amhsjournal.org/text.asp?2019/7/2/313/273053 |journal=Archives of Medicine and Health Sciences |language=en |volume=7 |issue=2 |doi=10.4103/amhs.amhs_118_19 |issn=2321-4848 |access-date=2022-06-22 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616204102/https://www.amhsjournal.org/text.asp?2019%2F7%2F2%2F313%2F273053 }}</ref>

关于更常见的不良反应，在29项临床试验中暴露于左氧氟沙星的7537名患者的汇总结果中，4.3%的患者因药物不良反应而停止治疗。导致停药的最常见不良反应是胃肠道反应，包括恶心、呕吐和便秘。总体而言，7%的患者出现恶心、6%的头痛、5%的腹泻、4%的失眠，以及其他发生率较低的不良反应。<ref name="fda" />

左氧氟沙星或其他广谱抗生素的施用与[[艰难梭菌|艰难梭菌]]相关的腹泻有关，其严重程度可能从轻度腹泻到致命的[[偽膜性結腸炎|结肠炎]]。 氟喹啉给药可能与特别剧毒梭菌菌株的获得和生长有关。<ref>{{Cite journal |last=Vardakas |first=Konstantinos Z. |last2=Konstantelias |first2=Athanasios A. |last3=Loizidis |first3=Giorgos |last4=Rafailidis |first4=Petros I. |last5=Falagas |first5=Matthew E. |date=2012-11 |title=Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis |url=https://pubmed.ncbi.nlm.nih.gov/22921930 |journal=International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases |volume=16 |issue=11 |doi=10.1016/j.ijid.2012.07.010 |issn=1878-3511 |pmid=22921930 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613074157/https://pubmed.ncbi.nlm.nih.gov/22921930/ }}</ref>

需要更多的研究来确定最佳剂量和治疗时间。<ref name="dovepress">{{Cite journal |last=McGregor |first=Jessina C. |last2=Allen |first2=George P. |last3=Bearden |first3=David T. |date=2008-10 |title=Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |url=https://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--peer-reviewed-fulltext-article-TCRM |journal=Therapeutics and Clinical Risk Management |volume=4 |issue=5 |doi=10.2147/tcrm.s3426 |issn=1176-6336 |pmc=2621400 |pmid=19209267 |access-date=2022-06-13 |archive-date=2022-06-22 |archive-url=https://web.archive.org/web/20220622062800/https://pubmed.ncbi.nlm.nih.gov/19209267/ }}</ref>

== 过量服用 ==
在动物身上进行的过量实验显示出身体失去控制和下垂、呼吸困难、震颤和抽搐。 超过1500mg/kg口服和250mg/kg IV的剂量在啮齿动物中产生了显着的死亡率。<ref name="fda" />

如果发生急性过量用药，当局建议采用非特定的标准程序，例如排空胃、观察患者和保持适当的水合作用。[[血液透析|血液透析]]或[[腹膜透析|腹膜透析]]不能有效去除左氧氟沙星。<ref name="fda" />

== 药理 ==
=== 作用机制 ===
左氧氟沙星是一种广谱抗生素，对革兰氏阳性菌和革兰氏阴性菌均有效。与所有喹诺酮类药物一样，它通过抑制[[DNA旋转酶|DNA旋转酶]]和拓扑异构酶IV（两种细菌II型拓扑异构酶）发挥作用。<ref>{{Cite journal |last=Drlica |first=K. |last2=Zhao |first2=X. |date=1997-09 |title=DNA gyrase, topoisomerase IV, and the 4-quinolones |url=https://pubmed.ncbi.nlm.nih.gov/9293187 |journal=Microbiology and molecular biology reviews: MMBR |volume=61 |issue=3 |doi=10.1128/mmbr.61.3.377-392.1997 |issn=1092-2172 |pmc=232616 |pmid=9293187 |access-date=2022-06-13 |archive-date=2022-04-21 |archive-url=https://web.archive.org/web/20220421220957/https://pubmed.ncbi.nlm.nih.gov/9293187/ }}</ref>拓扑异构酶IV是分离细菌细胞分裂前已复制（加倍）的[[脱氧核糖核酸|DNA]]所必需的。由于DNA没有被[[DNA复制|分离]]，这个过程就停止了，细菌就不能分裂。另一方面，DNA旋转酶负责使[[DNA超螺旋|DNA超螺旋]]，使其适合新形成的细胞。这两种机制都相当于杀死细菌。左氧氟沙星起到杀菌剂的作用。<ref>{{Cite book|edition=8., völlig neu bearb. und erw. Aufl|title=Arzneimittelwirkungen : Lehrbuch der Pharmakologie und Toxikologie ; mit einführenden Kapiteln in die Anatomie, Physiologie und Pathophysiologie ; 272 Tabellen|url=https://www.worldcat.org/oclc/48723029|publisher=Wiss. Verl.-Ges|date=2001|location=Stuttgart|isbn=3-8047-1763-2|oclc=48723029|first=Ernst|last=Mutschler}}</ref>

截至2011年，该药物对肌肉骨骼并发症的作用机制尚不清楚。<ref name="wiley" />

=== 药代动力学 ===
左氧氟沙星在口服给药后迅速且基本完全吸收，其血浆浓度随时间变化的曲线与静脉给药相同量超过60分钟的血浆浓度基本相同。因此，左氧氟沙星的静脉内和口服制剂被认为是可以互换的。<ref name="fda" />左氧氟沙星与体内蛋白质结合的能力范围为24%至38%。<ref name="dovepress" />

该药物广泛分布到身体组织中。给药后3小时达到皮肤中的峰值水平，超过血浆中的2倍。同样，单次给药后24小时内，肺组织浓度比血浆浓度高2倍至5倍。

单次或多次口服或静脉内给予左氧氟沙星后，左氧氟沙星的平均终末血浆消除半衰期约为6至8小时。消除主要通过尿液中未代谢的药物的排泄而发生。口服给药后，87%的给药剂量在2天内以原形药物形式从尿液中回收。尿液中只有不到5%的去甲基和N-氧化物代谢物是在人体中发现的唯一代谢物。

== 化学 ==
与所有氟[[喹诺酮|喹诺酮]]类药物一样，左氧氟沙星是一种氟化喹诺酮类[[羧酸|羧酸]]。它是一种手性分子，是外消旋药物氧氟沙星的纯(-)-(S)-[[对映异构|对映]]体。<ref>{{Cite web |title=STATISTICAL REVIEW AND EVALUATION |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020634-4.pdf |website=Drug Databases |format=PDF |language=en-US |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616064406/https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020634-4.pdf }}</ref><ref>{{Cite journal |last=Morrissey |first=I. |last2=Hoshino |first2=K. |last3=Sato |first3=K. |last4=Yoshida |first4=A. |last5=Hayakawa |first5=I. |last6=Bures |first6=M. G. |last7=Shen |first7=L. L. |date=1996-08 |title=Mechanism of differential activities of ofloxacin enantiomers |url=https://pubmed.ncbi.nlm.nih.gov/8843280 |journal=Antimicrobial Agents and Chemotherapy |volume=40 |issue=8 |doi=10.1128/AAC.40.8.1775 |issn=0066-4804 |pmc=163416 |pmid=8843280 |access-date=2022-06-15 |archive-date=2022-06-21 |archive-url=https://web.archive.org/web/20220621151322/https://pubmed.ncbi.nlm.nih.gov/8843280/ }}</ref><ref>{{Cite journal |last=Kannappan |first=Valliappan |last2=Mannemala |first2=Sai Sandeep |date=2014-09 |title=Multiple Response Optimization of a HPLC Method for the Determination of Enantiomeric Purity of S-Ofloxacin |url=http://link.springer.com/10.1007/s10337-014-2699-4 |journal=Chromatographia |language=en |volume=77 |issue=17-18 |doi=10.1007/s10337-014-2699-4 |issn=0009-5893}}</ref>这种对映异构体与 DNA 促旋酶和拓扑异构酶 IV 的结合比其 (+)-(R)-对应物更有效。<ref name="dovepress" />左氧氟沙星被称为手性开关：这些手性药物已经获得专利，已作为[[外消旋体|外消旋体]]或[[非对映异构体|非对映异构体]]混合物[[权利要求|获得专利]]、批准和销售，<ref>{{Cite book|title=Introduction to stereochemistry|url=https://www.worldcat.org/title/introduction-to-stereochemistry/oclc/1097808137|publisher=W.A. Benjamín|date=1966|location=New York|oclc=1097808137|first=Kurt|last=Mislow|access-date=2022-06-13|archive-date=2022-06-19|archive-url=https://web.archive.org/web/20220619084149/https://www.worldcat.org/title/introduction-to-stereochemistry/oclc/1097808137}}</ref>但后来被重新开发为纯对映异构体。<ref>{{Cite journal |last=Agranat |first=null |last2=Caner |first2=null |date=1999-07 |title=Intellectual property and chirality of drugs |url=https://pubmed.ncbi.nlm.nih.gov/10377509 |journal=Drug Discovery Today |volume=4 |issue=7 |doi=10.1016/s1359-6446(99)01363-x |issn=1878-5832 |pmid=10377509 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613075926/https://pubmed.ncbi.nlm.nih.gov/10377509/ }}</ref>该分子上的不同官能团包括羟基、羰基和芳环。<ref>{{Cite journal |last=Mouzam |first=Md Ismail |last2=Dehghan |first2=M. H. G. |last3=Asif |first3=Shaikh |last4=Sahuji |first4=Trupti |last5=Chudiwal |first5=Pooja |date=2011-04 |title=Preparation of a novel floating ring capsule-type dosage form for stomach specific delivery |url=https://pubmed.ncbi.nlm.nih.gov/23960746 |journal=Saudi pharmaceutical journal: SPJ: the official publication of the Saudi Pharmaceutical Society |volume=19 |issue=2 |doi=10.1016/j.jsps.2011.01.004 |issn=1319-0164 |pmc=3745050 |pmid=23960746 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613075928/https://pubmed.ncbi.nlm.nih.gov/23960746/ }}</ref>

该物质以半[[水合物|水合物]]形式使用，其经验式为 C<sub>18</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>·½H<sub>2</sub>O，分子量为370.38g/mol。左氧氟沙星为淡黄白色至黄白色结晶或结晶性粉末。<ref name="fda" />左氧氟沙星合成中的一个主要问题是确定正确进入苯并恶嗪核心以产生正确的手性形式。<ref>{{Cite journal |last=Bower |first=John F. |last2=Rujirawanich |first2=Janjira |last3=Gallagher |first3=Timothy |date=2010-04-07 |title=N-heterocycle construction via cyclic sulfamidates. Applications in synthesis |url=https://pubmed.ncbi.nlm.nih.gov/20237659 |journal=Organic & Biomolecular Chemistry |volume=8 |issue=7 |doi=10.1039/b921842d |issn=1477-0539 |pmid=20237659 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613075928/https://pubmed.ncbi.nlm.nih.gov/20237659/ }}</ref>

== 历史 ==
左氧氟沙星是第三代氟喹诺酮类药物，是氧氟沙星的异构体之一，是[[诺氟沙星|诺氟沙星]]的广谱构象锁定类似物；氧氟沙星和左氧氟沙星都是由[[第一三共|第一三共]]的科学家合成和开发的。<ref>{{Cite book|title=Drug discovery : a history|url=https://www.worldcat.org/oclc/62301847|publisher=Wiley|date=2005|location=Hoboken, N.J.|isbn=0-470-01552-7|oclc=62301847|first=Walter|last=Sneader}}</ref>第一制药的科学家们知道氧氟沙星是外消旋体，但试图分离这两种异构体没有成功；1985年，他们成功地分别合成了纯左旋形式，并表明它比另一种形式毒性更小，效力更强。<ref name="fr">{{Cite web |first=Terry |last=Mahn |title=New FDA Requirements for Post-Marketing Studies and Clinical Trials: Patent Strategy |url=https://www.fr.com/files/Uploads/attachments/memoranda/memorANDAQ209.pdf |website=Fish |format=PDF |language=en |access-date=2022-06-13 |archive-date=2022-06-19 |archive-url=https://web.archive.org/web/20220619002217/https://www.fr.com/files/Uploads/attachments/memoranda/memorANDAQ209.pdf }}</ref><ref name="infectweb">{{Cite web |first=Shogo |last=Atarashi |title=Research and Development of Quinolones in Daiichi Sankyo Co, Ltd. |url=http://www.infectweb.com/only/03_SpeFeature.pdf |website=Infection Update |format=PDF |language=en |access-date=2022-06-13 |archive-date=2016-10-12 |archive-url=https://web.archive.org/web/20161012025535/http://www.infectweb.com/only/03_SpeFeature.pdf }}</ref>

它于1993年首次获准在日本上市，用于口服给药，第一制药以Cravit品牌在日本上市。<ref name="infectweb" />第一制药与[[强生公司|强生公司]]合作，于1996年以商品名Levaquin获得FDA批准<ref name="fr" />，用于治疗细菌性鼻窦炎、支气管炎细菌性加重、社区获得性肺炎、单纯性皮肤感染、复杂性尿路感染和急性肾盂肾炎。<ref name="fda" />

左氧氟沙星由[[赛诺菲|赛诺菲]]根据1993年与第一制药签署的许可协议以Tavanic品牌销售。<ref name="genericsweb">{{Cite web |date=2010-10 |first=Katie |last=Taylor |title=GenericsWeb - The Search is Over |url=https://web.archive.org/web/20140112065215/http://www.genericsweb.com/druginfocus/Levofloxacin |website=GenericsWeb |access-date=2022-06-13}}</ref>

此时，左氧氟沙星已达到重磅炸弹的地位。2009年，仅强生公司在全球范围内的左氧氟沙星和氧氟沙星销售额合计为16亿美元。<ref name="genericsweb" />

[[File:Levofloxacin.jpg|thumb]]注射液，规格为100mL/750mg]]

根据药品价格竞争与专利期补偿法案的规定，美国专利商标局将左氧氟沙星美国专利的期限延长了810天，因此该专利将在2010年而不是2008年到期。<ref name="fr" />

这一延期受到仿制药制造商Lupin Pharmaceuticals的质疑，该公司没有质疑专利的有效性，而只是质疑专利延期的有效性，认为该专利不涵盖“产品”，因此药品价格竞争与专利期补偿法案不适用于扩展名。<ref name="fr" />

联邦专利法院作出有利于强生和第一制药的裁决，左氧氟沙星的仿制药直到2009年才进入美国市场。<ref name="fr" /><ref name="fr" />

== 社会与文化 ==
=== 可用性 ===
左氧氟沙星有片剂、注射剂和口服溶液。<ref name="fda" />

=== 使用情况 ===
FDA估计，2011年，美国有超过2300万张氟喹诺酮类门诊处方，其中左氧氟沙星占28%。<ref>{{Cite journal |last=Research |first=Center for Drug Evaluation and |date=2013-08-15 |title=FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection |url=https://www.fda.gov/Drugs/DrugSafety/ucm365050.htm |journal=FDA |language=en |access-date=2022-06-13 |archive-date=2016-05-28 |archive-url=https://web.archive.org/web/20160528231716/http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm }}</ref>

=== 诉讼 ===
截至2012年，强生公司面临大约3400起州和联邦诉讼，这些诉讼由声称左氧氟沙星造成肌腱损伤的人提起；约1900人在明尼苏达州美国地方法院的集体诉讼中待决，<ref>{{Cite web |title=Levaquin MDL |url=http://www.mnd.uscourts.gov/MDL-Levaquin/index.shtml |website=District of Minnesota |access-date=2022-06-13 |archive-date=2009-11-24 |archive-url=https://web.archive.org/web/20091124200542/http://www.mnd.uscourts.gov/MDL-Levaquin/index.shtml }}</ref>约1500人在新泽西州地方法院待决。<ref>{{Cite web |title=Litigation Over J&J Antibiotic, Levaquin, Designated N.J. Mass Tort |url=https://www.law.com/njlawjournal/almID/1202431900084/ |website=New Jersey Law Journal |language=en |access-date=2022-06-13 |archive-date=2022-06-16 |archive-url=https://web.archive.org/web/20220616064747/https://www.law.com/njlawjournal/almID/1202431900084/ }}</ref><ref name="bloomberg">{{Cite news|title=Johnson & Johnson Settles 845 Levaquin Lawsuits|url=https://www.bloomberg.com/news/articles/2012-11-01/johnson-johnson-reaches-settlement-in-845-levaquin-cases|newspaper=Bloomberg.com|date=2012-11-01|accessdate=2022-06-13|language=en|archive-date=2021-09-17|archive-url=https://web.archive.org/web/20210917204819/https://www.bloomberg.com/news/articles/2012-11-01/johnson-johnson-reaches-settlement-in-845-levaquin-cases}}</ref>

2012年10月，强生在明尼苏达州的诉讼中解决了845起案件，此前强生公司在前四起案件中的三起胜诉，进入审判阶段。 截至2014年5月，除363起案件外，其余案件均已结案或宣判。<ref name="bloomberg" /><ref>{{Cite web |date=2012-11-01 |first=Margaret |last=Cronin Fisk |first2=Beth |last2=Hawkins |title=Johnson & Johnson Settles 845 Levaquin Lawsuits - Businessweek |url=http://www.businessweek.com/news/2012-11-01/johnson-and-johnson-reaches-settlement-in-845-levaquin-cases |website=Businessweek.com |access-date=2022-06-15 |archive-date=2012-11-05 |archive-url=https://web.archive.org/web/20121105073224/http://www.businessweek.com/news/2012-11-01/johnson-and-johnson-reaches-settlement-in-845-levaquin-cases }}</ref><ref>{{Cite web |date=2012-10-26 |title=Levaquin MDL |url=https://web.archive.org/web/20121026164940/http://www.mnd.uscourts.gov/MDL-Levaquin/current-developments.shtml |website=United States District Court - District of Minnesota |access-date=2022-06-15}}</ref>

== 参考文献 ==
{{Reflist|4}}

== 外部链接 ==
* {{Cite web |title=Levofloxacin |url=https://druginfo.nlm.nih.gov/drugportal/name/Levofloxacin |publisher=U.S. National Library of Medicine |website=Drug Information Portal |language=en |access-date=2022-06-15 |archive-date=2021-12-10 |archive-url=https://web.archive.org/web/20211210002053/https://druginfo.nlm.nih.gov/drugportal/name/levofloxacin }}

{{核酸合成抑制剂类抗生素}}
{{Portal bar|医学}}

[[Category:对映纯药物|Category:对映纯药物]]
[[Category:楊森製藥|Category:楊森製藥]]
[[Category:日本发明|Category:日本发明]]
[[Category:吗啉|Category:吗啉]]
[[Category:赛诺菲|Category:赛诺菲]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:哌嗪|Category:哌嗪]]